Literature DB >> 10571818

p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma.

A Sato1, R MacHinami.   

Abstract

In order to evaluate the usefulness of p53 immunohistochemistry (IHC) in the diagnosis of ulcerative colitis-associated colorectal carcinoma (UCACRC), ordinary paraffin sections were examined in 61 cases with ulcerative colitis (UC) and 29 control cases without UC. Among the 61 cases with UC, 11 were complicated by carcinoma coexisting with dysplasia, three with dysplasia, and two cases with adenoma. There were a total of 38 dysplasias, including 33 low grade dysplasias (LGD) and five mixed low and high grade dysplasias (LGD + HGD). The results of p53 IHC were divided into diffuse, nested, scattered and sporadic patterns for 29 control cases. Diffuse and nested patterns were presumed to reflect mutant forms of p53 protein and were defined as overexpression of p53 protein. In non-neoplastic mucosa of UC, the frequency of p53 positive tubules was significantly higher in active phase (13.5-17.9%) than in resolving phase (3.9-6.5%) and in remission (0.7-2.4%), regardless of association with neoplasia. Eight of the 37 lesions of dysplasia (21. 6%) showed p53 overexpression: 12.5% in LGD and 80.0% in LGD + HGD. The rate of p53 overexpression was significantly higher in UCACRC (90.9%) than in non-neoplastic mucosa of UC (0%), LGD and sporadic colorectal carcinoma (54.5%), but it did not differ between UCACRC and LGD + HGD. Interestingly, the mucosa without dysplasia showed p53 overexpression in one case of UCACRC. The biopsy specimen taken 4 years before the diagnosis of carcinoma revealed p53 overexpression in another case with UCACRC. These results suggest that p53 abnormalities play an important role in UC-associated tumorigenesis in its relatively early phase. For the diagnosis of dysplasia and carcinoma in UC, p53 IHC seems to be useful.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571818     DOI: 10.1046/j.1440-1827.1999.00965.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  14 in total

1.  p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease.

Authors:  Jeffrey W Nathanson; Nicole E Yadron; Jeanne Farnan; Sydney Kinnear; John Hart; David T Rubin
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

2.  Surveillance for colitis-associated colon neoplasia.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 3.  Novel diagnostic and therapeutic techniques for surveillance of dysplasia in patients with inflammatory bowel disease.

Authors:  Marietta Iacucci; T Uraoka; M Fort Gasia; N Yahagi
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

4.  Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer.

Authors:  Ziad Kanaan; Shesh N Rai; M Robert Eichenberger; Christopher Barnes; Amy M Dworkin; Clayton Weller; Eric Cohen; Henry Roberts; Bobby Keskey; Robert E Petras; Nigel P S Crawford; Susan Galandiuk
Journal:  Hum Mutat       Date:  2012-03       Impact factor: 4.878

Review 5.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

6.  Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis.

Authors:  Pavel Wohl; Tomas Hucl; Pavel Drastich; David Kamenar; Julius Spicak; Eva Honsova; Eva Sticova; Alena Lodererova; Jan Matous; Martin Hill; Petr Wohl; Milos Kucera
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

7.  Dynamics of Genome Alterations in Crohn's Disease-Associated Colorectal Carcinogenesis.

Authors:  Karoline Horisberger; Thomas Ried; Timo Gaiser; Daniela Hirsch; Darawalee Wangsa; Yuelin J Zhu; Yue Hu; Daniel C Edelman; Paul S Meltzer; Kerstin Heselmeyer-Haddad; Claudia Ott; Peter Kienle; Christian Galata
Journal:  Clin Cancer Res       Date:  2018-07-02       Impact factor: 12.531

8.  Molecular characterization of ulcerative colitis-associated colorectal carcinomas.

Authors:  Daniela Hirsch; Julia Hardt; Christian Sauer; Kerstin Heselmeyer-Hadded; Stephanie H Witt; Peter Kienle; Thomas Ried; Timo Gaiser
Journal:  Mod Pathol       Date:  2020-12-14       Impact factor: 7.842

9.  TP53/p53 alterations and Aurora A expression in progressor and non-progressor colectomies from patients with longstanding ulcerative colitis.

Authors:  Mariann Friis-Ottessen; Espen Burum-Auensen; Aasa R Schjølberg; Per Olaf Ekstrøm; Solveig N Andersen; Ole Petter Clausen; Paula M De Angelis
Journal:  Int J Mol Med       Date:  2014-10-20       Impact factor: 4.101

10.  Immunohistochemical assessment of a unique basal pattern of p53 expression in ulcerative-colitis-associated neoplasia using computer-assisted cytometry.

Authors:  Shunsuke Kobayashi; Takahiro Fujimori; Hiroyuki Mitomi; Shigeki Tomita; Kazuhito Ichikawa; Johji Imura; Shigehiko Fujii; Michihiro Itabashi; Shingo Kameoka; Yoshinori Igarashi
Journal:  Diagn Pathol       Date:  2014-05-29       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.